The efficacy of intralymphatic administration of Diamyd®, an antigen specific immunotherapy aimed at stopping the immune systems attack on the beta cells in autoimmune diabetes, is being confirmed in the Phase IIb trial DIAGNODE-2.
Remygen®, a product aimed at stimulating the regrowth of beta cells in patients with diabetes, will be evaluated in patients for the first time in 2018. In addition, Diamyd® is being evaluated in different combinations in ongoing investigator-initiated trials.